| | | | | S-1 | | | |
| | | | | S-6 | | | |
| | | | | S-11 | | | |
| | | | | S-13 | | | |
| | | | | S-14 | | | |
| | | | | S-17 | | | |
| | | | | S-18 | | | |
| | | | | S-19 | | | |
| | | | | S-23 | | | |
| | | | | S-24 | | | |
| | | | | S-30 | | | |
| | | | | S-30 | | | |
| | | | | S-31 | | | |
| | | | | S-31 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 10 | | | |
| | | | | 17 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 22 | | |
| | |
Fiscal year
|
| |||||||||||||||||||||||||||
| | |
2018
|
| |
2019
|
| |
2020
|
| |
1Q2020
|
| |
1Q2021
|
| |||||||||||||||
Cash flow from operations(1)
|
| | | | 291 | | | | | | 219 | | | | | | 3 | | | | | | (33) | | | | | | 22 | | |
Capital expenditures/investments
|
| | | | 128 | | | | | | 99 | | | | | | 50 | | | | | | 16 | | | | | | 8 | | |
Free cash flow (non-GAAP)
|
| | | | 163 | | | | | | 119 | | | | | | (47) | | | | | | (49) | | | | | | 13 | | |
| | |
Fiscal Year
|
| |||||||||||||||||||||||||||
| | |
2018
|
| |
2019
|
| |
2020
|
| |
1Q2020
|
| |
1Q2021
|
| |||||||||||||||
Net Income (GAAP)
|
| | | | 99 | | | | | | 127 | | | | | | (277) | | | | | | (136) | | | | | | (1) | | |
Tax expense
|
| | | | 8 | | | | | | 13 | | | | | | (103) | | | | | | (55) | | | | | | 2 | | |
Interest & other expense, net
|
| | | | 7 | | | | | | 2 | | | | | | 9 | | | | | | 2 | | | | | | 3 | | |
Depreciation & amortization expense
|
| | | | 96 | | | | | | 88 | | | | | | 91 | | | | | | 24 | | | | | | 22 | | |
Gain on investments in unconsolidated affiliates
|
| | | | 5 | | | | | | (39) | | | | | | — | | | | | | — | | | | | | — | | |
Dividends on Series A preferred stock
|
| | | | — | | | | | | — | | | | | | 13 | | | | | | — | | | | | | 5 | | |
Direct & incremental Series A preferred stock issuance costs
|
| | | | — | | | | | | — | | | | | | 10 | | | | | | — | | | | | | — | | |
EBITDA (non-GAAP)
|
| | | | 215 | | | | | | 192 | | | | | | (256) | | | | | | (166) | | | | | | 31 | | |
Impairment of assets and lease terminations
|
| | | | 18 | | | | | | 18 | | | | | | 219 | | | | | | 192 | | | | | | 1 | | |
Acquisition-related costs
|
| | | | — | | | | | | 5 | | | | | | 3 | | | | | | 1 | | | | | | — | | |
Acquisition-related contingent consideration and amortization expense
|
| | | | — | | | | | | 1 | | | | | | (4) | | | | | | (4) | | | | | | | | |
COVID-19 related costs
|
| | | | — | | | | | | — | | | | | | 23 | | | | | | 3 | | | | | | 5 | | |
Adjusted EBITDA (non-GAAP)
|
| | | | 233 | | | | | | 216 | | | | | | (15) | | | | | | 25 | | | | | | 38 | | |
| | |
As of March 30, 2021
|
| |||||||||||||||||||||
| | |
Actual
|
| |
As adjusted
|
| |
As further
adjusted |
| |
Pro forma
as further adjusted |
| ||||||||||||
| | |
(In thousands, except share and per share data)
|
| |||||||||||||||||||||
Cash and cash equivalents
|
| | | $ | 181,345 | | | | | $ | | | | | $ | | | | | $ | | | |||
Debt: | | | | | | | | | | | | | | | | | | | | | | | | | |
Revolving credit facility(1)(2)
|
| | | $ | 280,000 | | | | | $ | 280,000 | | | | | $ | 280,000 | | | | | $ | 280,000 | | |
Principal amount of % convertible senior notes due 2026 we are offering pursuant to the concurrent offering(3)
|
| | | | — | | | | | | — | | | | | | 300,000 | | | | | | 300,000 | | |
Total debt
|
| | | | 280,000 | | | | | | 280,000 | | | | | | 580,000 | | | | | | 580,000 | | |
Series A convertible preferred stock, $0.01 par value per share; 200,000 shares authorized, 200,000 shares issued and outstanding, actual, as adjusted and as further adjusted; no shares issued and outstanding, pro forma as further adjusted
|
| | | | 213,485 | | | | | | 213,485 | | | | | | 213,485 | | | | | | — | | |
Stockholders’ equity: | | | | | | | | | | | | | | | | | | | | | | | | | |
Preferred stock, $0.01 par value per share, other
than Series A convertible preferred stock; 4,800,000 shares authorized, no shares issued and outstanding, actual, as adjusted, as further adjusted and pro forma as further adjusted |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Common stock, $0.01 par value per share; 250,000,000 shares authorized; 99,508,470 shares outstanding, actual; shares outstanding, as adjusted and as further adjusted; shares outstanding, pro forma as further adjusted(4)
|
| | | | 995 | | | | | | | | | | | | | | | | | | | | |
Additional paid-in capital(3)
|
| | | | 904,045 | | | | | | | | | | | | | | | | | | | | |
Retained earnings(5)
|
| | | | 1,114,047 | | | | | | 1,114,047 | | | | | | 1,114,047 | | | | | | 1,114,047 | | |
Treasury stock, 53,101,293 shares at cost, actual, as adjusted, as further adjusted and pro forma as further adjusted
|
| | | | (1,700,700) | | | | | | (1,700,700) | | | | | | (1,700,700) | | | | | | (1,700,700) | | |
Accumulated other comprehensive loss
|
| | | | (1,873) | | | | | | (1,873) | | | | | | (1,873) | | | | | | (1,873) | | |
Total stockholders’ equity(3)(5)
|
| | | | 316,514 | | | | | | | | | | | | | | | | | | | | |
Total capitalization(3)(5)
|
| | | $ | 809,999 | | | | | $ | | | | | $ | | | | | $ | | | |
Underwriter
|
| |
Number of Shares
|
| |||
J.P. Morgan Securities LLC
|
| | | | | | |
BNP Paribas Corp.
|
| | | | | | |
BofA Securities, Inc.
|
| | | | | | |
Wells Fargo Securities, LLC
|
| | | | | | |
Total
|
| | | | | |
| | |
Paid by The Cheesecake Factory
Incorporated |
| |||||||||
| | |
No
|
| |
Full
|
| ||||||
| | |
Exercise
|
| |
exercise
|
| ||||||
Per Share
|
| | | $ | | | | | $ | | | ||
Total
|
| | | $ | | | | | $ | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 10 | | | |
| | | | | 17 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 22 | | |
/
B
M3])&FE*EIZ)E95.4KM%/'QHGJYY442 ;79\F9]/M-:I:3UQ<0LC8*73.2G(Q&!;
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M_=]8ZN=&5/,GNI:6 8=L$@[((B)B^\ O+B+5QY [?C5%9J*NNDO:5K,7!0N]J2*BJRCOJ HS*Q:MNV"2]\0@+/(/
M+R)1"(:[?Q_E&7C&1@$$80YX%(GQ.M5'?8;MPKBRS4!AT%U,@\XO"5K#4XQ(
M!/BQD55O73/A7[!$DO!LNFI;LG+SG S4[(I$'^!8LX#2GW\ZV-0NS"J":EVQ
MK%/,$3.8M606<,RK,>LVLG9Q E"M=H#,TQ)RQH,6_1(^VC. J:W#!!05B50$
ML %%K+ Y"@D>W>UUC;"($2H"O-=5?"D=
M%Q=>$O.0_C)')E,JL:9.[:H#_,,38;'E0
$;IWI6&J>V6OO[)VW<,H9H%6UE5*Z.\QJR2SR1* H&".2
M.(O!!TTKTM[=3"D:5:6ND*7"E0#*P2), U4$*I7D)]S%B]GNSSW7445/D0U
MU[F$@C=15X>-4WFS.2-"A0P/=SV V9& *F4/HB#RV=,>7C+"S'?7 $*E0XFJ
M0CHZS>Q"SNKW:1IVLJ.$P.P)BT0N80DB.V.&0#C)K?,T:=&N5FAC+RPNGW$I
M:?&2?11@'KG/N"+@7/\ JO\ *>WG[ =^M